News

The two companies are partnering to develop a population health management platform solution that leverages CliniWorks’ technologies in disparate data aggregation and Natural Language Processing (which interprets free

The approval makes VIMIZIM the first and only pharmaceutical treatment option available in Canada for children and adults living with this severely debilitating, progressive and life-limiting disorder. "Morquio

Under the terms of the agreement, Mariel acquired the rights to over 450 issued and pending patents, Stryker’s BMP-7-related clinical and research data, and the associated biologic materials.

BGB-290 is an investigational, oral, selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP), an enzyme family which is involved in a number of cellular processes, including DNA

GKAs have the potential to differentiate from other anti-diabetic agents by exerting two potentially beneficial actions: promoting insulin secretion and decreasing glucose production by the liver. As a

BEMA buprenorphine is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in

U.S. Patent No. 8,673,292, titled "Pure Populations of Astrocyte Restricted Percursor Cells and Methods for Isolation and Use Thereof," covers the astrocyte family of neural cells of the

The agreement is expected to allow ORGS to advance its manufacturing (GMP) process from lab scale to clinical scale as it prepares for Phase I and Phase II

Both, PSP and CBD represent diseases of the central nervous system and are collectively called as tauopathies, and for which no FDA approved therapies exist. The Phase I